☰

James Wightman Davidson - Publications

Affiliations: 
University of Cambridge, Cambridge, England, United Kingdom 
Tree Info Similar researchers PubMed Report error

7 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Szlavik Z, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Murray J, Davidson J, Chen I, Dokurno P, Surgenor AE, Daniels ZM, Hubbard RE, et al. Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor. Journal of Medicinal Chemistry. PMID 33146521 DOI: 10.1021/acs.jmedchem.0c01234  0.368
2019 Szlávik Z, Ondi L, Csékei M, Paczal A, Szabó ZB, Radics G, Murray J, Davidson J, Chen I, Davis B, Hubbard RE, Pedder C, Dokurno P, Surgenor A, Smith J, et al. Structure-Guided Discovery of a Selective Mcl-1 Inhibitor with Cellular Activity. Journal of Medicinal Chemistry. PMID 31339316 DOI: 10.1021/Acs.Jmedchem.9B00134  0.394
2019 Maragno AL, Mistry P, Kotschy A, Szlavik Z, Murray J, Davidson J, Toumelin-Braizat GL, Chanrion M, Bruno A, Claperon A, Maacke H, Morris E, Wang Y, Derreal A, Csekei M, et al. Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models Cancer Research. 79: 4482-4482. DOI: 10.1158/1538-7445.Am2019-4482  0.393
2018 Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, Bruno A, Chanrion M, Lysiak-Auvity G, Le Diguarher T, Starck JB, Chen I, Whitehead N, Graham C, Matassova N, Dokurno P, et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 9: 20075-20088. PMID 29732004 DOI: 10.18632/oncotarget.24744  0.391
2018 Casara P, Davidson J, Claperon A, Toumelin-Braizat GL, Vogler M, Bruno A, Chanrion M, Lysiak-Auvity G, Diguarher TL, Starck J-, Chen I, Whitehead N, Graham C, Matassova N, Dokurno P, et al. S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth. Oncotarget. 9: 20075-20088. DOI: 10.2210/Pdb6Gl8/Pdb  0.397
2016 Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. PMID 27760111 DOI: 10.1038/Nature19830  0.377
2012 Geneste O, Murray J, Diguarher TL, Starck J, Casara P, Nanteuil GD, Davidson J, Nunns C, Graham C, Matassova N, Chen I, Whitehead N, Dokurno P, Bruno A, Pierré A, et al. Abstract 2782: Bcl-2 selective antagonists show antitumor activity without dose limiting platelet toxicity Cancer Research. 72: 2782-2782. DOI: 10.1158/1538-7445.Am2012-2782  0.4
Show low-probability matches.